AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 111 min read$GUTS

Rajagopalan Harith purchased $18K of GUTS

Rajagopalan Harith (Chief Executive Officer) purchased 25,000 shares of FRACTYL HEALTH, INC. (GUTS) at $0.73 on 2026-06-10.

Original reporting
SEC EDGAR · Rajagopalan Harith
Published Jun 11, 2026, 8:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 11, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$GUTS
Bullish
low confidence
Mentioned
$GUTS
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GUTSBullishLow
01

Why it matters

The newest concrete fact is the CEO’s open-market purchase of 25,000 shares at $0.7301/share, which may slightly improve sentiment but lacks fundamental follow-through in the text.

02

Market read

Traders may treat this as a small sentiment input, but it is unlikely to drive a major repricing without additional company catalysts.

03

What to watch

The article provides only the transaction details; it does not include prior insider activity frequency, option exercises, or any concurrent operational/company catalysts.

Relevance 4/10Novelty 8/10Timing: Filed 2026-06-11; purchase dated 2026-06-10

Background

The filing is an SEC Form 4 insider transaction for FRACTYL HEALTH, INC. (GUTS).

Company-level read

Ticker impact

$GUTSBullishLow confidence
Context

CEO Rajagopalan Harith bought 25,000 shares of FRACTYL HEALTH (GUTS) in an open-market Form 4 on 2026-06-10.

Expected impact

Likely limited/short-lived impact; more relevant for monitoring insider confidence than for a standalone trade.

Evidence & confidence

The disclosure is a Form 4 insider purchase with no accompanying company-specific news (no guidance, deal, or regulatory action).

Market effects

Sector

No sector read-across; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buys under a non-10b5-1 plan can still be routine liquidity/portfolio actions and may not signal near-term upside.

Key entities

  • issuer
    FRACTYL HEALTH, INC.

    Company whose shares were purchased by its CEO via an open-market transaction.

  • insider
    Rajagopalan Harith

    CEO and director who reported the purchase on Form 4.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GUTS insider trading history →

Related articles

SEP 1
$GUTSMedAI 8/10

Fractyl Health shares rise 2.8% ahead of Virtual Commercial Strategy Day

Fractyl Health (GUTS) shares rose 2.8% pre-market ahead of a Virtual Commercial Strategy Day. The company will discuss its Revita therapy's commercial strategy and market opportunity, following positive REMAIN-1 clinical data. Analysts have differing ratings, with Bank of America issuing a 'Buy' and Morgan Stanley a 'Hold'. The company targets FDA application in late 2026.

finance.yahoo.com1 min
SEP 1
$GUTSMed

Why is Fractyl Health stock gaining today?

Fractyl Health (GUTS) stock rose 2.8% in pre-market trading ahead of its Virtual Commercial Strategy Day, where management will discuss the commercial strategy for Revita, its procedural therapy. Recent clinical data showed patients maintained 84% of GLP-1-induced weight loss. Analysts from Bank of America and Morgan Stanley have differing ratings. The move is driven by company-specific catalysts, not broader market trends.

investing.com2 min
AUG 10
$GUTSMed

FRACTYL HEALTH, INC. (GUTS): Results of Operations and Financial Condition

FRACTYL HEALTH, INC. (GUTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates One-year REMAIN-1 Midpoint Cohort data show Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in patients receiving complete duodenal ablation

SEC EDGAR 8-K6 min
JUL 15
MedAI 8/10

Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars - Fractyl Health (

Fractyl Health reported one-year results for its Revita procedure in a 45-participant modified intention-to-treat group. Revita cut weight regain versus sham, with least-squares mean regain of 7.8% vs 13.0%. In higher-intensity duodenal ablation subgroups, it preserved about 81% to 84% of GLP-1 weight loss. Safety was similar between groups. Shares rose 19.54% to $0.85.

benzinga.com3 min
JUL 15
$GUTSMedAI 8/10

Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation

Fractyl Health (Nasdaq: GUTS) reported one-year, randomized sham-controlled REMAIN-1 midpoint cohort results for its Revita DMR system after GLP-1 discontinuation. In mITT (N=45), weight regain was 7.8% vs 13.0% with sham. Complete duodenal ablation (>14 cm) retained ~81% vs 48% with sham. No device-related serious AEs. Next: six-month pivotal topline in early Q4 2026 and possible FDA De Novo late Q4 2026.

manilatimes.net5 min